Highlights
- The PREVENT trial suggests that preventive percutaneous coronary intervention (PCI) for non-flow-limiting vulnerable plaques significantly reduces major adverse cardiac events compared to optimal medical therapy (OMT) alone.
- Advanced intracoronary imaging (IVUS, OCT, NIRS) has reached a diagnostic maturity that allows for the precise identification of high-risk plaque features like thin fibrous caps and large lipid cores.
- Despite clinical benefits in composite endpoints, the lack of significant reduction in hard mortality data and the open-label nature of current trials fuel an ongoing debate regarding the ‘default’ status of this intervention.
- Residual cardiovascular risk remains high under OMT, but the rapid evolution of lipid-lowering and anti-inflammatory drugs presents a moving target for the incremental value of mechanical stabilization.
Background
For decades, the management of coronary artery disease (CAD) has been dichotomized into treating hemodynamically significant, flow-limiting stenoses and managing non-obstructive atherosclerosis with pharmacological agents. However, pathological and clinical evidence suggests that the majority of acute myocardial infarctions (AMIs) arise from plaques that do not cause significant luminal narrowing before the event. These so-called ‘vulnerable plaques’—characterized by a thin fibrous cap, a large necrotic core, and high inflammatory activity—represent a ‘silent’ threat that current physiology-guided strategies (such as FFR-guided PCI) often overlook.
While Optimal Medical Therapy (OMT), including high-intensity statins, PCSK9 inhibitors, and anti-platelet agents, has drastically improved outcomes, a substantial ‘residual risk’ persists. This has led to the provocative hypothesis: Can we preemptively ‘seal’ these vulnerable plaques with stents or scaffolds to prevent future rupture, effectively changing the natural history of the disease? This debate has reached a fever pitch following the publication of the PREVENT trial and earlier studies like PROSPECT-ABSORB.
Key Content
The Identification of the Vulnerable Plaque: Imaging Evolution
The transition from ‘vulnerable plaque’ as a post-mortem pathological concept to a clinical target was made possible by advances in intracoronary imaging. Three primary modalities dominate the current landscape:
- Intravascular Ultrasound (IVUS): Provides deep penetration to assess plaque burden and remodeling. Large plaque burden (>70%) and small luminal areas are established predictors of future events.
- Optical Coherence Tomography (OCT): Offers near-histological resolution (10–20 μm), allowing for the measurement of the fibrous cap thickness. A thickness of <65 μm is the hallmark of a Thin-Cap Fibroatheroma (TCFA).
- Near-Infrared Spectroscopy (NIRS): Specifically identifies lipid content, providing a Lipid Core Burden Index (LCBI). A high maxLCBI in a 4mm segment is a potent predictor of periprocedural and spontaneous MI.
Pivotal Clinical Trials and the Evidence for Intervention
The evidence for preventive PCI has evolved through several landmark studies:
1. The PROSPECT Study (2011): This natural history study demonstrated that non-obstructive lesions with a large plaque burden, small lumen area, or TCFA morphology were responsible for a significant proportion of future MACE, nearly equal to the risk posed by the original ‘culprit’ lesion treated at baseline.
2. PROSPECT-ABSORB (2020): This was the first randomized attempt to treat these lesions. Using Bioresorbable Vascular Scaffolds (BVS), the trial showed that ‘sealing’ vulnerable plaques was safe and resulted in a significantly larger minimal lumen area at follow-up, though it was underpowered for hard clinical endpoints.
3. The PREVENT Trial (2024/2026): The most definitive evidence to date. This large-scale randomized trial compared preventive PCI plus OMT versus OMT alone in patients with non-flow-limiting vulnerable plaques (identified by IVUS/NIRS/OCT). The primary composite endpoint (cardiac death, MI, ischemia-driven revascularization, or unstable angina) was significantly lower in the PCI group. This trial challenged the long-held belief that non-ischemic lesions should be left alone.
Mechanistic Insights into Plaque Stabilization
The biological rationale for preventive PCI rests on ‘mechanical passivation.’ By deploying a drug-eluting stent (DES) over a TCFA, the procedure provides a synthetic ‘cap’ that prevents the thrombogenic core from contacting the bloodstream should the underlying natural cap rupture. Furthermore, the drug eluted from the stent may locally suppress the inflammatory milieu of the plaque. This dual mechanical-biological stabilization aims to transform a high-risk lesion into a stable, fibrotic one.
The Counter-Argument: Why OMT Should Remain the Standard
Critics of the ‘default PCI’ strategy raise several valid concerns:
- The ‘Moving Target’ of OMT: Modern OMT is vastly more potent than the regimens used in early plaque studies. With the advent of inclisiran, GLP-1 receptor agonists, and colchicine, the baseline risk of plaque rupture is decreasing, potentially narrowing the absolute benefit of PCI.
- Procedural Risks: PCI is not benign. Iatrogenic risks such as stent thrombosis, side-branch occlusion, and the lifelong requirement for dual antiplatelet therapy (DAPT) must be weighed against a future event that may never occur.
- Soft Endpoints: In the PREVENT trial, the benefit was largely driven by a reduction in revascularization and unstable angina. Critics argue that in an open-label trial, knowing a stent is present may bias clinicians and patients against further intervention, whereas ‘untreated’ patients are more likely to be sent for revascularization if they present with any chest pain.
Expert Commentary
The debate surrounding Park et al.’s findings in the European Heart Journal reflects a fundamental shift in interventional cardiology. Historically, we have been ‘reactive’—waiting for ischemia to manifest on a stress test or FFR wire. The PREVENT data suggests we should be ‘proactive’ in high-risk phenotypes.
However, applying this to the ‘default’ treatment of every non-flow-limiting plaque is premature. Clinical applicability should likely be reserved for ‘high-risk patients with high-risk plaques.’ For instance, a diabetic patient with multivessel disease and a large lipid-rich plaque in the proximal LAD (Left Anterior Descending) artery represents a vastly different risk profile than an elderly patient with a stable calcified lesion in a distal vessel.
Furthermore, we must address the cost-effectiveness. Routine use of triple-modality imaging and stenting for non-obstructive disease would place an enormous burden on healthcare systems. The focus should shift toward identifying the ‘vulnerable patient’—perhaps using polygenic risk scores or inflammatory biomarkers (like hsCRP)—to select who benefits most from the invasive imaging and subsequent preventive PCI.
Conclusion
The inclusion of preventive PCI in the treatment armamentarium for non-flow-limiting vulnerable plaques represents one of the most significant shifts in CAD management in the last decade. The evidence from the PREVENT trial provides a strong signal of benefit, particularly in reducing composite ischemic events. However, before it becomes the ‘default’ treatment, the cardiology community requires long-term data on stent-related complications and larger trials powered specifically for hard outcomes like cardiovascular mortality.
In the interim, a personalized approach—utilizing intracoronary imaging to characterize plaque morphology in patients already undergoing coronary angiography—offers a middle ground. The future of CAD management lies in the synergy of aggressive systemic pharmacotherapy and targeted mechanical stabilization of the ‘ticking time bombs’ within the coronary tree.
References
- Park DW, et al. Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques. European Heart Journal. 2026. PMID: 41790132.
- Stone GW, et al. A Prospective Natural-History Study of Coronary Atherosclerosis. N Engl J Med. 2011;364:226-235. PMID: 21247313.
- Stone GW, et al. Clinical Outcomes of State-of-the-Art Percutaneous Coronary Intervention in High-Risk Nonflow-Limiting Lesions: The PROSPECT-ABSORB Randomized Trial. JACC. 2020. PMID: 32981610.
- Park DW, et al. Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Plaques (PREVENT): A Multicentre, Open-label, Randomised Controlled Trial. The Lancet (presented at ACC 2024).
- Kedhi E, et al. Thin-cap fibroatheroma and outcome of FFR-guided strategy: The COMBINE (OCT-FFR) study. Eur Heart J. 2021. PMID: 33275739.
